Key terms
About SAGE
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SAGE news
Today
8:35am ET
SAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor Setbacks
Today
8:08am ET
Balancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial Reassessment
Today
7:29am ET
Scotiabank Remains a Buy on SAGE Therapeutics (SAGE)
Today
6:37am ET
SAGE Therapeutics (SAGE) Receives a Hold from RBC Capital
Today
5:06am ET
Sell Rating on Sage Therapeutics Amid Zurzuvae Sales Concerns and Pipeline Risks
Today
2:21am ET
SAGE Therapeutics’ Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold Rating
Yesterday
2:25pm ET
Hold Rating on SAGE Therapeutics Amid Limited Revenue Prospects and Pipeline Uncertainty
Yesterday
11:30am ET
Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and SAGE Therapeutics (SAGE)
Yesterday
11:12am ET
Sage Therapeutics price target lowered to $20 from $26 at Stifel
Yesterday
7:55am ET
SAGE Therapeutics: Hold Rating Amidst Mixed Financial and Market Signals
Yesterday
6:47am ET
Sage Therapeutics reports Q1 EPS ($1.80), consensus ($1.65)
Apr 22
1:31am ET
Analysts Conflicted on These Healthcare Names: SAGE Therapeutics (SAGE), Accolade (ACCD) and Intuitive Surgical (ISRG)
Apr 19
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Apr 19
8:42am ET
SAGE Therapeutics Adjusts Inducement Equity Plan and Sets End Date
Apr 18
9:23am ET
Sage Therapeutics price target lowered to $19 from $34 at Scotiabank
Apr 18
7:36am ET
Sage Therapeutics price target lowered to $17 from $25 at Oppenheimer
Apr 18
7:10am ET
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE), Poseida Therapeutics (PSTX) and Align Tech (ALGN)
Apr 18
5:25am ET
SAGE Therapeutics: Hold Rating Reiterated Amid Clinical Trial Setbacks and Uncertainties
Apr 17
11:30am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Palisade Bio (PALI)
Apr 17
11:18am ET
H.C. Wainwright concerned over Sage’s next readouts after SAGE-718 miss
Apr 17
11:08am ET
RBC ‘not altogether surprised’ by Sage move lower after failure in PD
Apr 17
9:37am ET
Sage Therapeutics cut to Underperform at BofA after Parkinson’s trial fails
Apr 17
9:34am ET
Sage Therapeutics downgraded to Underperform from Neutral at BofA
Apr 17
8:03am ET
Sage Therapeutics down 19% at $12.60 after announcing dalzanemdor Phase 2 data
Apr 17
6:52am ET
SAGE Therapeutics’ Promising Parkinson’s Treatment Results
Apr 17
6:34am ET
Sage announces Phase 2 study of dalzanemdor did not meet primary endpoint
Apr 09
6:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)
Mar 28
4:55am ET
Sage Therapeutics management to meet with Piper Sandler
Mar 27
9:50pm ET
Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)
Mar 26
8:42am ET
SAGE Therapeutics Board Member Announces Retirement
Mar 26
6:12am ET
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics, Inc. (APGE), SAGE Therapeutics (SAGE)
SAGE Financials
Key terms
Ad Feedback
SAGE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SAGE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
